Estats Units - anglès - NLM (National Library of Medicine)

biogen inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 30 ug in 0.5 ml - avonex is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. avonex is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation [see warnings and precautions (5.3)] . the formerly available lyophilized vial formulation of avonex is contraindicated in patients with a history of hypersensitivity to albumin (human). risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interfer

Estats Units - anglès - NLM (National Library of Medicine)

guna spa - aldesleukin (unii: m89n0q7eqr) (aldesleukin - unii:m89n0q7eqr), everlasting extract (unii: kqv867adr4) (everlasting extract - unii:kqv867adr4), fomitopsis pinicola fruiting body (unii: 30d02u2irn) (fomitopsis pinicola fruiting body - unii:30d02u2irn), interferon gamma-1b (unii: 21k6m2i7ag) (interferon gamma-1b - unii:21k6m2i7ag), metenkefalin (unii: 9jez9od3as) (metenkefalin - unii:9jez9od3as), reishi (unii: tkd8lh0x2z) (reishi - unii:tkd8lh0x2z), brown rice (unii: 659g217hpg) (brown rice - unii:659g - aldesleukin 5 [hp_c] in 4 g - beta endorphin        4c    pain reliever blood            4c    immune support interferon  gamma    3c    immune support interleukin 2        5c    immune support life everlasting    3x    cold sores ling chin mushroom    8x    immune support lymphatic  gland    4c 7c    immune support melatonin        4c 15c    antioxidant rice            3x    immune support serotonin        6x    neurotransmitter soybean            3x    antioxidant spleen            4c    immune support turkey tail        8x    antioxidant temporary relief of symptoms due to viral infection such as: - upper respiratory congestion - sore throat - cold sores

Estats Units - anglès - NLM (National Library of Medicine)

hadaf llc - lapine interferon gamma immune globulin 12c, 30c, 50c purpose: enchance magnitude of immune response, lapine histamine immune globulin 12c, 30c, 50c purpose: reduce histamine and inflammation response, lapine cd4 immune globulin 12c, 30c, 50c purpose: enhance functional activity of immune system - homeopathic, enhance magnitude of immune response reduce histamine and inflammation response enhance functional activity of immune system • shorten the duration of flu and cold symptoms • reduce severity of flu and cold symptoms, including nasal congestion, cough and sore/itchy throat stop use and ask a doctor if symptoms persist or worsen. do not use if known sensitivity to brillia health cold-flu recover y or any of its ingredients exists.

Israel - anglès - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

Estats Units - anglès - NLM (National Library of Medicine)

merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (peginterferon alfa-2b - unii:g8rgg88b68) - peginterferon alfa-2b 40 ug in 0.1 ml - sylatron™ is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. sylatron is contraindicated in patients with: - a history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b - autoimmune hepatitis - hepatic decompensation (child-pugh score >6 [class b and c]) risk summary based on findings from animal studies, sylatron can cause embryo-fetal harm when administered to a pregnant woman. available human data with sylatron use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. administration of nonpegylated interferon alfa-2b was abortifacient in rhesus monkeys at doses approximately 13 times higher than the recommended dose of 6 mcg/kg/week (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage is 2-4% and

Estats Units - anglès - NLM (National Library of Medicine)

emd serono, inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 8.8 ug in 0.2 ml - rebif is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation. risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta in pregnancy have been inconsistent (see data) . it is unclear whether, as a class of products, administration of interferon beta therapies to pregnant animals at doses greater than those used clinically results in an increased rate of abortion. the potential for rebif to have adverse effects on em

Israel - anglès - Ministry of Health

medison pharma ltd - interferon beta 1a - solution for injection - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

Israel - anglès - Ministry of Health

bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -